Autologous ovalbumin-specific type 1 T lymphocyte cell therapy - TxCell

Drug Profile

Autologous ovalbumin-specific type 1 T lymphocyte cell therapy - TxCell

Alternative Names: Autologous ovalbumin-specific regulatory T lymphocytes - TxCell; Crohn's disease autologous T cell therapy - TxCell; Ova-Treg - TxCell; Ovalbumin-specific Type 1 Treg cells - TxCell; OvaSave®

Latest Information Update: 06 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator TxCell
  • Class Anti-inflammatories; Cell therapies; Regulatory T lymphocyte cell therapies
  • Mechanism of Action Immunosuppressants; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Crohn's disease

Most Recent Events

  • 06 Feb 2018 Discontinued - Phase-II for Crohn's disease (Treatment-resistant) in France, United Kingdom, Italy, Austria, Germany and Belgium (IV) (Not listed on TxCell pipeline, February 2018)
  • 24 Nov 2016 TxCell terminates the phase II CATS29 trial in Crohn's disease (Treatment-resistant) in Austria, Belgium, France, Germany, Italy and United Kingdom (NCT02327221)
  • 31 May 2016 Pharmacodynamics data from the phase I/II CATS1 trial in Crohn's disease released by TxCell
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top